Monosomy 22 syndrome
mah-noh-soh-mee twen-tee-too sin-drohm
Also known as: Partial Monosomy 22, 22q11.2 Deletion Syndrome
At a Glance
What is Monosomy 22 syndrome?
Monosomy 22 syndrome is a genetic disorder caused by the deletion of a small piece of chromosome 22. This condition affects multiple body systems, including the heart, immune system, and facial structure. It is caused by a missing segment of chromosome 22, which can occur randomly or be inherited. Over time, individuals may experience developmental delays, learning disabilities, and immune deficiencies. Early symptoms often include heart defects and characteristic facial features, while later symptoms can involve speech and cognitive challenges. Early diagnosis is critical for managing health issues and planning interventions. The condition can significantly impact family life, requiring ongoing medical care and support. Prognosis varies, but many individuals lead fulfilling lives with appropriate medical and educational interventions. Daily life may involve regular medical appointments, therapies, and educational support. Families often need to adapt their routines to accommodate the needs of the affected individual. Support groups and resources can be invaluable for families navigating this condition. Awareness and understanding of the syndrome are essential for improving outcomes and quality of life.
Medical Definition
Monosomy 22 syndrome, also known as 22q11.2 deletion syndrome, is characterized by the deletion of a segment of chromosome 22 at the q11.2 region. Pathologically, this deletion results in a wide range of clinical manifestations due to the loss of multiple genes. Histologically, affected tissues may show abnormalities consistent with the specific organ systems involved, such as cardiac defects or thymic hypoplasia. The syndrome is classified under chromosomal deletion syndromes and is one of the most common microdeletion syndromes. Epidemiologically, it affects approximately 1 in 4,000 to 1 in 6,000 live births. The disease course is variable, with some individuals experiencing severe complications and others having milder symptoms.
Monosomy 22 syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Cardiac anomalies in Monosomy 22 syndrome often manifest as congenital heart defects such as ventricular septal defects. These defects are caused by improper development of the heart during embryogenesis due to the chromosomal deletion. Over time, these heart defects can lead to complications such as heart failure or pulmonary hypertension if not managed appropriately. Daily life can be significantly affected, requiring regular monitoring and possibly surgical intervention to correct the defects and prevent further complications.
Facial dysmorphism includes features such as a small jaw, low-set ears, and a prominent nose. These features arise from the disrupted development of craniofacial structures during embryonic growth due to the chromosomal anomaly. As the child grows, these features become more pronounced but generally do not worsen over time. While they do not typically affect physical health, they can impact social interactions and self-esteem, necessitating supportive care and possibly surgical correction for cosmetic reasons.
Immune deficiency in Monosomy 22 syndrome presents as recurrent infections due to a reduced number of T-cells. This deficiency is caused by the underdevelopment of the thymus gland, which is crucial for T-cell maturation. Over time, the frequency and severity of infections can increase if the immune deficiency is not addressed. Daily life is affected by the need for frequent medical care and preventive measures, such as vaccinations and prophylactic antibiotics, to manage infections.
Common
Developmental delay is characterized by slower than expected progress in reaching developmental milestones such as speech and motor skills. This delay is due to the impact of the chromosomal deletion on brain development and function. As the child ages, the gap in developmental progress compared to peers may widen without intervention. Early intervention programs, including physical, occupational, and speech therapy, can help improve developmental outcomes and quality of life.
A cleft palate is an opening in the roof of the mouth that occurs when the tissue does not fuse properly during fetal development. This condition is directly linked to the chromosomal deletion affecting craniofacial development. If untreated, it can lead to feeding difficulties, speech problems, and increased risk of ear infections. Surgical correction is typically required to close the cleft and improve function, often followed by speech therapy to address any residual speech issues.
Hearing loss in Monosomy 22 syndrome can be conductive or sensorineural, resulting from structural abnormalities in the ear or nerve damage. The chromosomal deletion affects the development of the auditory system, leading to these impairments. Over time, untreated hearing loss can hinder language development and social interactions. Hearing aids, cochlear implants, and regular audiological assessments are essential to manage the condition and support communication skills.
Less Common
Hypocalcemia is a condition characterized by low levels of calcium in the blood, often presenting with muscle cramps and seizures. It occurs due to underdevelopment of the parathyroid glands, which regulate calcium levels, as a result of the chromosomal deletion. Without treatment, hypocalcemia can lead to long-term complications such as osteoporosis. Management involves calcium and vitamin D supplementation to maintain normal calcium levels and prevent symptoms.
Renal anomalies may include structural abnormalities such as a single kidney or horseshoe kidney. These anomalies arise from disrupted kidney development during embryogenesis due to the chromosomal deletion. Over time, renal function may be compromised, leading to issues such as hypertension or chronic kidney disease. Regular monitoring of kidney function and blood pressure, along with lifestyle modifications, are crucial to managing these anomalies and preventing complications.
What Causes Monosomy 22 syndrome?
Monosomy 22 syndrome is primarily caused by the deletion of genetic material on chromosome 22, specifically involving the 22q11.2 region. This region contains several genes, including TBX1, which plays a crucial role in embryonic development. The TBX1 gene encodes a transcription factor that is involved in the regulation of developmental processes, particularly in the formation of the heart, thymus, and parathyroid glands. Mutations or deletions affecting TBX1 disrupt its ability to bind DNA and regulate the expression of target genes, leading to impaired organ development. Inside the cell, this results in altered signaling pathways and reduced cell proliferation, affecting tissue growth and differentiation. The dysfunction of these pathways can lead to defects in the development of the cardiovascular system, immune system, and craniofacial structures. Neuroinflammation may be triggered as the body attempts to compensate for developmental anomalies, potentially exacerbating neurological symptoms. White matter degeneration may occur due to disrupted myelination processes, affecting neural connectivity and function. Symptoms appear in a specific pattern due to the critical roles of the affected genes during particular stages of development, leading to characteristic features such as cardiac anomalies, immune deficiencies, and facial dysmorphisms. The variability in disease severity among patients can be attributed to the extent of the deletion, the presence of additional genetic or environmental factors, and individual differences in compensatory mechanisms. Other genes in the 22q11.2 region, such as COMT and PRODH, may also contribute to the phenotypic variability observed in patients. The involvement of multiple genes and pathways underscores the complexity of the syndrome and its wide-ranging effects on different organ systems. The interplay between genetic predisposition and environmental influences further complicates the clinical presentation and progression of the disease. Understanding the molecular basis of monosomy 22 syndrome is crucial for developing targeted therapies and improving patient outcomes. Continued research is needed to elucidate the full spectrum of genetic and epigenetic factors involved in this condition.
How is Monosomy 22 syndrome Diagnosed?
Typical age of diagnosis: Monosomy 22 syndrome is typically diagnosed in infancy or early childhood when characteristic clinical features and developmental delays become apparent. Diagnosis often occurs after parents or pediatricians notice developmental delays or congenital anomalies.
The clinician looks for characteristic facial features, congenital heart defects, and developmental delays. A detailed family and prenatal history is important to identify any genetic predispositions or complications during pregnancy. Physical examination may reveal craniofacial anomalies, cardiac murmurs, and hypotonia. This step helps to determine the need for further genetic and imaging studies.
Echocardiography is commonly used to identify congenital heart defects such as ventricular septal defects or tetralogy of Fallot. MRI or CT scans may reveal structural brain anomalies or other organ malformations. Imaging findings can confirm the presence of physical anomalies associated with the syndrome and help exclude other conditions with similar presentations. These studies are crucial for planning further diagnostic and therapeutic interventions.
Basic metabolic panels and complete blood counts are ordered to assess general health and identify any metabolic imbalances. Immunological tests may reveal T-cell deficiencies, which are common in this syndrome. Abnormal results, such as low calcium levels or immunodeficiencies, guide the clinician towards a diagnosis of a chromosomal disorder. These findings prompt genetic testing for confirmation.
Chromosomal microarray analysis or karyotyping is performed to detect deletions or duplications on chromosome 22. The tests may reveal a deletion at 22q11.2, which confirms the diagnosis of monosomy 22 syndrome. Identifying the genetic mutation aids in confirming the diagnosis and provides information for genetic counseling. Results inform family planning and potential recurrence risks in future pregnancies.
Monosomy 22 syndrome Treatment Options
Calcium supplements are used to manage hypocalcemia, a common issue in patients with monosomy 22 syndrome. They work by increasing calcium levels in the blood to prevent seizures and muscle spasms. Specific drugs include calcium carbonate and calcium citrate. Clinical evidence supports their efficacy in maintaining normal calcium levels, but they require regular monitoring to avoid hypercalcemia. Side effects may include gastrointestinal discomfort and potential interactions with other medications.
Developmental therapy employs techniques such as motor skill exercises and sensory integration to improve physical and cognitive abilities. The goal is to enhance motor coordination, communication skills, and social interactions. Sessions are typically conducted weekly and adjusted based on progress, with each lasting about 45 minutes. Measurable outcomes include improved motor milestones and enhanced social engagement. Long-term benefits include better quality of life and increased independence.
Cardiac surgery is indicated for congenital heart defects like ventricular septal defects. The procedure involves repairing the heart defect to improve cardiac function and oxygenation. Expected benefits include improved cardiac output and reduced symptoms of heart failure. Surgical risks include infection, bleeding, and anesthesia complications. Post-operative care requires monitoring in an intensive care unit and long-term follow-up with a cardiologist.
The care team typically includes pediatricians, cardiologists, geneticists, and therapists. Interventions focus on medical management, developmental support, and nutritional guidance. Psychosocial support strategies involve counseling and support groups for families. Family education is crucial for understanding the condition and managing daily challenges. Long-term monitoring includes regular follow-ups to assess growth, development, and emerging health issues.
When to See a Doctor for Monosomy 22 syndrome
- Severe difficulty breathing — this could indicate a life-threatening respiratory issue requiring immediate medical attention.
- Sudden loss of consciousness — this may be a sign of a critical neurological event or severe cardiac problem.
- Severe chest pain — this could indicate a cardiac emergency such as a heart attack.
- Persistent high fever — could suggest an underlying infection or inflammatory process that needs medical evaluation.
- Unexplained weight loss — may indicate a serious underlying condition that requires further investigation.
- Frequent infections — could be a sign of an immunological deficiency associated with the condition.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional headaches — keep track of frequency and intensity, and consult a doctor if they worsen.
Monosomy 22 syndrome — Frequently Asked Questions
Is this condition hereditary?
Monosomy 22 syndrome is typically not inherited but occurs due to a de novo mutation. The probability of passing it to children is low unless a parent has a balanced translocation. De novo mutations mean the genetic change occurs spontaneously. Carrier status can be determined through genetic testing. Genetic counseling is recommended for affected families to understand the risks and implications.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly depending on the severity of symptoms and associated anomalies. Early intervention and management of complications can improve outcomes. Mortality is often due to cardiac or immunological issues. Treatment can enhance quality of life and potentially extend survival. Realistic expectations should be discussed with healthcare providers, focusing on individual prognosis.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves genetic testing, often initiated after clinical suspicion based on symptoms. The time from first symptoms to diagnosis can vary, sometimes taking months. Specialists such as geneticists and pediatricians are typically involved. Delayed diagnosis may occur due to the rarity and variability of the condition. Confirmation is achieved through chromosomal analysis or microarray testing.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and targeted treatments. Novel approaches aim to address specific genetic and symptomatic aspects of the condition. ClinicalTrials.gov is a resource for finding relevant trials. Patients should discuss potential trials and treatments with their doctors. New treatments may take years to become widely available.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care, depending on the severity of physical anomalies. Educational challenges may arise, necessitating special support and adaptations. Social and emotional challenges are common, requiring psychological support. The family burden can be significant, with a need for comprehensive care strategies. Supportive therapies and adaptive technologies can help improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Immunologic, Molecular, and Clinical Profile of Patients with Chromosome 22q11.2 Duplications.
Bhattarai D, McGinn DE, Crowley TB et al. · J Clin Immunol · 2023 · PMID: 36735193
- 2.Partial monosomy 22 as result of an X/22 translocation in a newborn with DiGeorge syndrome.
Schwanitz G, Zerres K · Ann Genet · 1987 · PMID: 3314667
- 3.Full mosaic monosomy 22 in a child with DiGeorge syndrome facial appearance.
Pinto-Escalante D, Ceballos-Quintal JM, Castillo-Zapata I et al. · Am J Med Genet · 1998 · PMID: 9511978
- 4.CATCH 22 Syndrome.
Yonehara Y, Nakatsuka T, Ichioka S et al. · J Craniofac Surg · 2002 · PMID: 12218787
- 5.DiGeorge syndrome in a child with partial monosomy of chromosome 22.
Annerén G, Gustafsson J, Sunnegårdh J · Ups J Med Sci · 1989 · PMID: 2711536
- 6.Phelan-McDermid Syndrome.
Omansky GL, Abdulhayoglu E, Zhurbilo B · Neonatal Netw · 2017 · PMID: 28320496
- 7.17q12 microdeletion syndrome.
Bhargav VSLV, Venkatachari M, Arun Babu T · BMJ Case Rep · 2024 · PMID: 39510608
- 8.CATCH 22.
Hall JG · J Med Genet · 1993 · PMID: 8230153
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-03